Latest market price
31.26
-0.81-2.53%
Earnings
Down 2.5% — Earnings due 2026-11-04 — pre-report positioning.
Medium confidence
TA
Loading chart...
Snapshot
| Index | — | P/E | 148.86 | EPS (ttm) | 0.21 | Insider Own | 18.02% | Shs Outstand | 125.69M | Perf Week | -1.73% |
| Market Cap | 3.93B | Forward P/E | 23.82 | EPS next Y | 1.31 | Insider Trans | -0.42% | Shs Float | 109.51M | Perf Month | 24.24% |
| Enterprise Value | 3.80B | PEG | 2.47 | EPS next Q | 0.18 | Short Float | 18.71% | Perf Quarter | 20.09% | ||
| Income | 28.00M | P/S | 8.47 | EPS this Y | — | Short Ratio | 8.89 | Perf Half Y | 33.08% | ||
| Sales | 464.00M | P/B | 17.78 | EPS next Y | 173.44% | ROA | 5.84% | Short Interest | 20.49M | Perf YTD | 7.64% |
| Book/sh | 1.76 | P/C | 16.44 | EPS next 5Y | 60.16% | ROE | 15.05% | 52W High | 33.30 -6.13% | Perf Year | 25.44% |
| Cash/sh | 1.90 | P/FCF | 103.40 | EPS past 3/5Y | — | ROIC | 9.95% | 52W Low | 19.30 61.97% | Perf 3Y | 1218.99% |
| Dividend Est. | — | EV/EBITDA | 88.47 | Sales past 3/5Y | 354.68% — | Gross Margin | 91.14% | Volatility | 2.85% 4.77% | Perf 5Y | 44.32% |
| Dividend TTM | — | EV/Sales | 8.20 | EPS Y/Y TTM | — | Oper. Margin | 7.38% | ATR (14) | 1.29 | Perf 10Y | — |
| Dividend Ex-Date | — | Quick Ratio | 2.67 | Sales Y/Y TTM | 75.76% | Profit Margin | 6.15% | RSI (14) | 60.90 | Recom | 2.17 |
| Dividend Gr. 3/5Y | — | Current Ratio | 2.92 | EPS Q/Q | 184.62% | SMA20 | 6.69% | Beta | 1.60 | Target Price | 42.25 |
| Payout | 0.00% | Debt/Eq | 0.52 | Sales Q/Q | 58.54% | SMA50 | 16.71% | Rel Volume | 0.60 | Prev Close | 32.07 |
| Employees | 354 | LT Debt/Eq | 0.48 | Earnings | Nov 04 | SMA200 | 23.69% | Avg Volume | 2.52M | Price | 31.26 |
| IPO Date | Jan 31, 2020 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 99.73% 9.26% | Net Debt/EBITDA | -2.91 | Volume | 1,514,401 | Change | -2.53% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-19-26 | Reiterated | Guggenheim | Buy | $38 → $44 |
| Oct-15-26 | Initiated | Cantor Fitzgerald | Overweight | $48 |
| Oct-08-26 | Reiterated | Jefferies | Buy | $19 → $39 |
| Aug-06-26 | Reiterated | Morgan Stanley | Overweight | $51 → $38 |
| Aug-06-26 | Reiterated | Guggenheim | Buy | $38 |
| Feb-26-26 | Reiterated | HC Wainwright & Co. | Buy | $30 → $34 |
| Nov-28-25 | Reiterated | Mizuho | Outperform | $32 → $37 |
| Oct-30-25 | Reiterated | Goldman Sachs | Neutral | $37 → $29 |
| Oct-29-25 | Reiterated | H.C. Wainwright | Buy | $22 → $30 |
| Oct-29-25 | Reiterated | Mizuho Securities | Outperform | $18 → $32 |
Latest News· Times ET
Oct-28-26
Oct-28-2611:06AM
09:00AM
Arcutis Appoints Rob Scott, MD to Board of Directorsglobenewswire.com
Oct-27-26
Oct-27-2604:00PM
Oct-22-26
Oct-22-2608:30AM
Oct-21-26
Oct-21-2604:00PM
Oct-20-26
Oct-20-2604:54AM
Oct-15-26
02:36AM
Oct-09-26
Oct-09-2608:00AM
04:02AM
Oct-06-26
Oct-03-26
Oct-03-2604:44AM
Oct-02-26
Oct-02-2604:00PM
Sep-29-26
Sep-29-2609:15AM
Sep-21-26
Company
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata. Established in 2016, the company was initially named Arcutis, Inc. before changing to Arcutis Biotherapeutics, Inc. in October 2019. Its corporate headquarters are situated in Westlake Village, California.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 464 | 376 | 197 | 60 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 42 | 37 | 19 | 5 | — | — | — | — | — | |
| Gross Profit | 424 | 339 | 177 | 55 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 297 | 275 | 229 | 185 | — | — | — | — | — | |
| Research and Development | 91 | 77 | 76 | 111 | — | — | — | — | — | |
| Other Operating Expense | 0 | 0 | 1 | 0 | — | — | — | — | — | |
| Operating Income | 34 | -12 | -128 | -241 | — | — | — | — | — | |
| Interest Expense | 13 | 12 | 27 | 30 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 8 | 9 | 16 | 12 | — | — | — | — | — | |
| Net Income Before Taxes | 29 | -15 | -139 | -259 | — | — | — | — | — | |
| Income Taxes | 0 | 1 | 1 | 3 | — | — | — | — | — | |
| Consolidated Net Income | 28 | -16 | -140 | -262 | — | — | — | — | — | |
| Net Income From Continuing Operations | 28 | -16 | -140 | -262 | — | — | — | — | — | |
| Net Income | 28 | -16 | -140 | -262 | — | — | — | — | — | |
| EPS (Recurring) | 0.22 | -0.13 | -1.16 | -3.78 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 0.22 | -0.13 | -1.16 | -3.78 | — | — | — | — | — | |
| EPS (Diluted) | 0.21 | -0.13 | -1.16 | -3.78 | — | — | — | — | — | |
| EBITDA | 43 | 2 | -110 | -229 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 148.86 | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 8.83 | 9.81 | 8.56 | 3.71 | — | — | — | — | — | |
| Gross Margin | 91.38 | 90.16 | 89.85 | 91.67 | — | — | — | — | — | |
| Operating Margin | 7.33 | -3.19 | -64.97 | -401.67 | — | — | — | — | — | |
| Net Margin | 6.03 | -4.26 | -71.07 | -436.67 | — | — | — | — | — | |
| Shares Outstanding | 131 | 127 | 121 | 69 | — | — | — | — | — | |
| Market Capitalization | 4,095 | 3,688 | 1,686 | 223 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Welgus Howard G. | Director | Oct 15 '26 | Sale | 26.93 | 4,728 | 127,325 | 35,207 | Oct 19 |
| Welgus Howard G. | Director | Oct 15 '26 | Option Exercise | 7.93 | 4,094 | 32,458 | 39,935 | Oct 19 |
| Matsuda Masaru | Officer | Sep 16 '26 | Sale | 25.00 | 3,674 | 91,853 | 112,508 | Sep 18 |
| Welgus Howard G. | Director | Sep 15 '26 | Option Exercise | 7.93 | 4,096 | 32,475 | 40,571 | Sep 17 |
| Welgus Howard G. | Director | Sep 15 '26 | Sale | 24.18 | 4,730 | 114,371 | 35,841 | Sep 17 |
| Matsuda Masaru | Officer | Sep 08 '26 | Sale | 25.03 | 9,989 | 249,986 | 116,182 | Sep 10 |
| Curran Terrie | Director | Aug 27 '26 | Option Exercise | 8.30 | 38,200 | 317,180 | 50,578 | Aug 28 |
| Curran Terrie | Director | Aug 27 '26 | Sale | 25.03 | 27,052 | 677,095 | 23,526 | Aug 28 |
| Curran Terrie | Director | Aug 20 '26 | Option Exercise | 7.51 | 1,072 | 8,051 | 24,598 | Aug 24 |
| Curran Terrie | Director | Aug 20 '26 | Sale | 26.04 | 1,072 | 27,912 | 23,526 | Aug 24 |
| Burnett Patrick | Officer | Aug 19 '26 | Sale | 27.00 | 1,697 | 45,819 | 117,592 | Aug 21 |
| Welgus Howard G. | Director | Aug 17 '26 | Option Exercise | 7.93 | 4,096 | 32,475 | 41,205 | Aug 19 |
| Welgus Howard G. | Director | Aug 17 '26 | Sale | 26.18 | 4,730 | 123,835 | 36,475 | Aug 19 |
| Burnett Patrick | Officer | Aug 12 '26 | Option Exercise | 3.64 | 6,700 | 24,388 | 125,989 | Aug 13 |
| Burnett Patrick | Officer | Aug 12 '26 | Sale | 26.08 | 6,700 | 174,767 | 119,289 | Aug 13 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.